SSR182289A, a selective and potent orally active thrombin inhibitor

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 7, 2004, Pages 1713-1730

  Altenburger, Jean Michel ^a   Lassalle, Gilbert Y ^a   Matrougui, Mostapha ^a   Galtier, Daniel ^a   Jetha, Jean Claude ^a   Bocskei, Zsolt ^a   Berry, Christopher N ^a   Lunven, Catherine ^a   Lorrain, Janine ^a   Herault, Jean Pascal ^a   Schaeffer, Paul ^a   O'Connor, Stephen E ^a   Herbert, Jean Marc ^a  

^a SANOFI   (France)

Author keywords

Benzotriazol 1 yloxytris(dimethylamino)phosphonium hexafluorophosphate; BOP; Dimethylformamide; DMF; HBTU; L arg surrogate; Oral antithrombotic; SSR182289A; Tetrahydrofuranne; THF; Thrombin inhibitor

Indexed keywords

N [3 [[4 (5 AMINO 2 PYRIDINYL) 1 [4 (DIFLUOROMETHYLENE) 1 PIPERIDINYL]CARBONYL]BUTYLAMINO]SULFONYL](1,1' BIPHENYL 2 YL)ACETAMIDE; PALLADIUM; SSR 182289A; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MALE; MOUSE; NONHUMAN; SONOGASHIRA REACTION; SUZUKI REACTION; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; HUMANS; HYDROGEN BONDING; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLATELET AGGREGATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THROMBIN; THROMBOSIS;

LATEOLABRAX JAPONICUS;

EID: 12144289000     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.01.016     Document Type: Article

References (69)

1. Fenton J.W. Ann. N.Y. Acad. Sci. 485:1996;5.
2. Bar Shavit R., Benezra M., Sabbah, V., Dejana E., Vlodavsky, I., Wilner, G.D., Thrombin, Structure and Function, Berliner, L. J. (Ed.), 1992, 315.
3. Carney, D. H., Thrombin, Structure and Function, Berliner, L. J. (Ed.), 1992, 351
4. Garcia J.G.N., Aschner J.L., Malik A.B., Thrombin, Structure and Function, Berliner, L. J. (ed.), 1992, 397.
5. Doolittle R.F., Blombäck B. Nature. 202:1964;147.
6. Sherry S., Alkjaersig N., Fletcher A.P. Am. J. Physiol. 209:1965;577.
7. Hijikata-Okunomiya A., Okamoto S. Sem. Thromb. Hemost. 18:1992;135.
8. Kikumoto R., Tamao Y., Tezuka T., tonomura S., Hara H., Ninomiya K., Hijikata A., Okamoto S. Biochem. 23:1984;85.
9. Voigt B., Wagner G., Vieweg H., Markwardt F., Stürzebecher J., DD 236866.
10. Bajusz S., Barabas E., Tolnay P., Szell E., Bagdy D. Int. J. Peptide Protein Res. 123:1978;217.
11. Bagdy D., Barabas E., Szabo G., Bajusz S., Szell E. Thromb. Haem. 67(3):1992;357.
12. Tapparelli C., Metternich R., Ehrhardt C., Cook N.S. TIPS. 14:1993;366.
13. Lyle T.A. Persp. Drug. Disc. Des. 1994;453.
14. Balasubramanian B. N. Bioorg. Med. Chem. Symposia in print No 5 and references cited therein.
15. The Design of Synthetic Inhibitors of Thrombin, Claeson G.; Scully M. F. ; Kakkar V. V.; Deadman J. (Eds), 1993, Adv. Exp. Med. Biol., 340.
16. Kimball S.D. Blood Coagulation Fibrinolysis. 6:1995;511.
17. Scarborough R.M. Ann. Rep. Med. Chem. 30:1995;71.
18. Edmunds J.J., Rapundalo S.T. Ann. Rep. Med. Chem. 31:1996;51.
19. Ripka W.C., Vlasuk G.P. Ann. Rep. Med. Chem. 32:1997;71.
20. Vacca J.P. Ann. Rep. Med. Chem. 33:1998;81.
21. Willey M.R., Fisher J. Exp. Opin. Ther. Patents. 7(11):1997;1265.
22. Ripka W.C. Current Opinion in Chemical Biology. 1:1997;242.
23. Sanderson P.E.J., Naylor-Olsen A.M. Curr. Med. Chem. 5:1998;289.
24. Menear K. Curr. Med. Chem. 5:1998;457.
25. Menear K. Exp. Opin. Invest. Drugs. 8(9):1999;1373.
26. Sanderson P.E.J. Med. Res. Rev. 19(2):1999;179.
27. Rewinkel J.B.M., Adang A.E.P. Curr. Pharm. Des. 5:1999;1043.
28. Shen G.X. Curr. Drug Targets - Cardiovascular & Haematological Disorders. 1:2001;41.
29. Coburn C. A., Exp. Opin. Ther. Patents. 11(5):2002;721.
30. Hara H., Tamao Y., Kikumoto R., Okamoto S. Thromb. Haemost. 57(2):1987;165.
31. Imura Y., Stassen J.M., Vreys I., Lessaffre E., Gold H.K., Collen D. Thromb. Haemost. 68(3):1992;336.
32. Fitzegerald D. Ann. N.Y. Acad. Sci. 714:1994;41.
33. Gustafsson D., Nystrom J., Carlsson S., Bredberg U., Eriksson U., Gyzander E., Elg M., Antonsson T., Hoofmann K., Ungell A.etal. Thromb. Res. 101:2001;171.
34. Gustafsson D., Antonsson T., Bylund R., Eriksonn U., Gyzander E., Nilsson I., Elg M., Mattsson C., Deinum J., Pehrsson S.etal. Thromb. Haemost. 79:1998;110.
35. Berry C.N., Lassalle G., Lunven C., Altenburger J.M., Guilbert F., Lalé A., Hérault J.P., Lecoffre C., Pfersdorff C., Herbert J.M., O'Connor S.E. J. Pharmacol. Exp. Ther. 303:2002;1189.
36. Lorrain J., Millet L., Lechaire I., Lochot S., Ferrari P., Visconte C., Sainte-Marie M., Lunven C., Berry C.N., Schaeffer P., Herbert J.M., O'Connor S.E. J. Pharmacol. Exp. Ther. 304(2):2003;567.
37. Kikumoto R., Tamao Y., Okhubo K., Tezuka T., Tonomura S., Hijikata A., Okamoto S., EP008746.
38. Huang J., Widlanski T.S. Tet. Lett. 33:1992;2657.
39. Oxford, A. W.; Cavala, D. J., EP 242973
40. Valerio R.M., Alewood P.F., Johns R.B. Synthesis. 1988;786.
41. Okamoto, S.; Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Kezuka, T.; Tonomura, S.; Hijikata, A. DT 2655636
42. Altenburger, J. M.; Lassalle, G. Y. EP 718307.
43. Khelevin R.N. J. Org. Chem. USSR (Engl. Transl.). 20:1984;112.
44. Suzuki A. Synlett. 1992;207.
45. Miyaura N., Yanagi T., Suzuki A. Synth. Commun. 11:1981;513.
46. Hoshino Y., Miyaura N., Suzuki A. Bull. Chem. Soc. Jpn. 61:1988;3008.
47. Satoh M., Miyaura N., Suzuki A. Chem. Lett. 1989;1405.
48. Satoh M., Miyaura N., Suzuki A. Pure & Appl. Chem. 63:1991;419.
49. Oh-e Y., Miyaura N., Suzuki A. Synlett. 1990;221.
50. Sharp M.J., Snieckus V. Tetrahedron Lett. 26:1985;5997.
51. Barco A., Benetti S., Pollini G.P., Taddia R. Synthesis. 1974;877.
52. Sonogashira K., Tohda Y., Hagihara N. Tetrahedron Lett. 16:1975;4467.
53. Upasani R.B., Yang K.C., Acosta-Buncuel M., Konkoy C.S., Mc Lellam J.A., Woodward R.M., Lan N.C., Carter R.B., Haskinson J.E. J. Med. Chem. 40:1997;73.
54. Wheaton G.A., Burton D.J. J. Org. Chem. 48(7):1983;917.
55. Banner D.W., Hadvary P. J. Biol. Chem. 266(30):1991;20085.
56. Feng D.-M., Gardell S.J., Lewis S.D., Bock M.G., Chen Z., Freidinger R., Naylor-Olsen A.M., Ramjit H.G., Woltmann R., Baskin E.P., Lynch J.J., Lucas R., Shafer J.A., Dancheck K.B., Chen I.-W., Mao S.-S., Krueger J.A., Hare T.R., Mulichak A.R., Vacca J.P. J. Med. Chem. 40:1997;3726.
57. Sanderson P.E.J., Cutrona K.J., Dorsey B.D., Dyer D.L., McDonough C.M., Naylor-Olsen A.M., Chen I.-W., Chen Z., Cook J.J., Gardell S.J., Krueger J.A., Lewis S.D., Lin J.H., Lucas B.J. Jr., Lyly E.A., Lynch J.J. Jr., Stranieri M.T., Vastag K., Shafer J.A., Vacca J.P. Bioorg. Med. Chem. Lett. 8:1998;817.
58. Bush L.R. Cardiov. Drug Rev. 9(3):1991;247.
59. Jegham, S.; Defosse, G.; Purcell, T.; Shoemaker, J. EP507650.
60. Lassalle, G.; Purcell, T.; Galtier, D.; Williams, P. H.; Galli, F. EP0565396. A similar strategy was independently reported following this work: Misra R.N., Kelly Y.F., Brown B.R., Roberts D.G.M., Chang S., Seiler S.M. Bioorg. Med. Chem. Lett. 4(18):1994;2165.
61. Kikumoto R., Tamao Y., Okkubo K., Tezuka T., Tonomura S., Okamoto S., Funahara Y., Hijikata A. J. Med. Chem. 23:1980;830.
62. Kikumoto R., Tamao Y., Okkubo K., Tezuka T., Tonomura S., Okamoto S., Funahara Y., Hijikata A. J. Med. Chem. 23:1980;1293. see also ref 4.
63. Cremer G. Unpublished results. Extensive use of 2-amino-pyridines as P1 fragments in D-Phe-Pro sequences or pyridine/pyrazinone peptidomimetics has been published independently by Merck teams. Fend, D. M.; Bock, M. G.; Freidinger, R. M.; Vacca, J. P.; Dorsey, B. D.; WO 9631504. See ref 26. See also Sanderson P.E.J., Lyle T.A., Cutrona K.J., Dyer D.L., Dorsey B.D., McDonough C.M., Naylor-Olsen A.M., Chen I.-W., Chen Z., Cook J.J., Cooper C.M., Gardell S.J., Hare T.R., Frueger J.A., Lewis S.D., Lin J.H., Lucas B.J. Jr., Lyle E.A., Lynch J.J., Stranieri M.T., Vastag K., Yan Y., Shafer J.A., Vacca J.P. J. Med. Chem. 41:1998;4466.
64. Coburn C.A., Rush D.M., Williams P.D., Lyle E.A., Lewis S.D., Lucas B.J. Jr., Di Muzio-Mower J.M., Juliano M., Krueger J.A., Vastag K., Chen I.-W., Vacca J.P. Bioorg. Med. Chem. Lett. 10:2000;1069.
65. Bode W., Mayr I., Baumann U., Huber R., Stone S.K., Hofsteenge J. EMBO J. 8:1989;3467.
66. Bode W., Turk D., Karshirov A. Protein Sci. 1:1992;426.
67. Excessive lipophilicity of coagulation enzyme inhibitors have been reported to alter coagulation parameters and in vivo antithrombotic performance. See for example: Tucker T.J., Lumma W.C., Lewis S.D., Gardell S.J., Lucas B.J., Baskin E.R., Woltmann R., Lynch J.J., Lyle E.A., Appleby S.D., Chen I.W., Dancheck K.B., Vacca J.P. J. Med. Chem. 40:1997;1565.
68. Chou Y.L., Davey D.D., Eagen K.A., Griedel B.D., Karanjawala R., Phillips G.B., Sacchi K.L., Snaw K.J., Wu S.C., Lentz D., Liang A.M., Trinh L., Morissey M., Kochanny M.J. Bioorg. Med. Chem. Lett. 13:2003;507.
69. Altenburger J.M., Cremer G., Lassalle G., Matrougui M., WO0170736.